This guidance overviews CV risk stratification prior to receiving certain cancer therapies to minimize the risk of CV toxicity from cancer treatments
Cardio-Oncology is the cardiac care of cancer patients. Cardiac issues may develop during cancer treatment or may be pre-existing or may develop as late effects. There has been increasing recognition of these issues recently which has led to the development of the new sub-specialty of Cardio-Oncology bringing together multidisciplinary teams of cardiologists, oncologists and allied healthcare professionals. This 45-minute webinar with 15-mins lives Q&A, presented by Dr Daniel Lenihan (Washington, US) and moderated by Dr Arjun Ghosh (Barts Heart Centre and UCLH, UK) is designed for those interested in learning about how to set up a brand new Cardio-Oncology service at their centre. Dr Daniel Lenihan, MD is a Cardio-Oncologist specializing in cardiology, heart disease and advanced heart failure. He has experience in developing Cardio-Oncology programs at both Vanderbilt in Nashville and Washington University. He is the current President of the International Cardio-Oncology Society. Dr Arjun Ghosh is a consultant cardiologist at Barts Heart Centre and UCLH. He helped establish Cardio-Oncology services at both hospitals and is the first cardiologist in the Uk appointed specifically in Cardio-Oncology.
In the rapidly changing world of healthcare, there is an obvious momentum to establish a Cardio-Oncology program at a variety of institutions or practices. Each medical provider location has its own unique resources with a variety of potential solutions. Dr Lenihan has developed robust Cardio-Oncology programs at 3 major institutions around the country and can provide extensive recommended solutions for any specific situation.
A recent presentation by Drs Vijay Rao and Dan Lenihan provides an overview of the recent Centers of Excellence designation by IC-OS of leading institutions and programs around the world.
Developing ‘Best Practice’ in Cardio-oncology Cardiovascular toxicity has become a challenging issue during cancer therapy. A survey of oncologists in France reveals that respondents commonly (>90%) prescribe therapies that are associated with cardiotoxicity. interestingly, the survey shows that the assessment and management of the cardiovascular status of cancer patients is often inconsistent between oncologists before, during and after cancer therapy administration.
In 2002, Katharine Ray, a 27-year survivor of Hodgkin lymphoma, wanted work “that mattered” when she joined the staff of The Minnie Pearl Cancer Foundation (now PearlPoint Cancer Support) in Nashville, Tenn. A year later, at age 42, she received a diagnosis of stage 1 breast cancer, probably a result of radiation treatments she received when she was 14.
These podcasts are a timely resource for expanding your understanding of the growing field of Cardio-Oncology and all its dimensions
Learn how Dr Lenihan utilizes readily available cardiac biomarkers to promote cardiac safety during cancer therapy